56
Views
25
CrossRef citations to date
0
Altmetric
Commentaries

Industry Influence on Occupational and Environmental Public Health

Pages 107-117 | Published online: 20 Nov 2013

References

  • Egilman DS, Rankin Bohme S. Over a barrel: corporate cor-ruption of science and its effects on workers and the environ-ment. Int J Occup Environ Health. 2005; 11: 331–7. http:www.ijoeh.com.
  • LaDou J. Occupational medicine in the United States: a proposal to abolish workers' compensation and reestablish the public health model. Int J Occup Environ Health. 2006; 12: 154–68.
  • Sass JB, Castleman B, Wallinga D. Vinyl chloride: a case study of data suppression and misrepresentation. Environ Health Per-spect. 2005; 113: 809–12.
  • Richter E, Soskolne CL, LaDou J: Efforts to stop repression bias by protecting whistleblowers. Int J Occup Environ Health. 2001; 7: 68–71.
  • Kuehn RR. Suppression of environmental science. Am J Law & Med. 2004; 30: 333–69.
  • Mutetwa B, Chikonyora M, Dozva R, Mazibuko D. Chrysotile fibre levels in asbestos-cement manufacturing in Zimbabwe. African Newsletter on Occupational Health and Safety. 2005; 15: 66–68. http://www.ttl.fl/africannewsletter or http://www.ttl.fi/nr/rdonlyres/39784837-0345-4122-974d-822b6cec29ca/0/africannewsletter305.pdf.
  • Bailar JC 3rd, Ballal SG, Boback M, et al. FIOH-sponsored Newsletter misrepresents asbestos hazards in Zimbabwe. Int J Occup Environ Health. 2006; 12: 254–8.
  • Wiist WH. Public health and the anticorporate movement: rationale and recommendations. Am J Public Health. 2006; 96: 1370–5.
  • Samuels SW. Time to consider real environmental criminal laws? July 31, 2006. Internet message to LaDou J.
  • Teitelbaum D. Internet message to Sheldon Samuels, July 31, 2006.
  • LaDou J. The rise and fall of occupational medicine in the United States. Ana J Prey Med. 2002; 22: 285–95.
  • LaDou J. Occupational medicine: the case for reform. Arn J Prey Med. 2005; 28: 396–402.
  • Sass J. Lockheed Martin and the White House working Together to weaken regulation of chemicals leaching from military super-fund sites, Int J Occup Environ Health. 2004; 10: 330–4.
  • Breilh J, Branco JC, Castleman BI., et al Texaco and its consult-ants [letter], IntJ Occup Environ Health, 2005; 11: 217–20.
  • Egilman DS, Billings MA. Abuse of epidemiology: automobile manufacturers manufacture a defense to asbestos liability. Itati Occup Environ Health. 2005; 11: 360–71.
  • Egilman DS, Scout. Corporate corruption of science: the case ofchromium (VI). Int J Occup Environ Health. 2006; 12: 169–76.
  • Scout, Egilman D. The case of chromium (VI). Int J Occur) Env-iron Health. 2006; 12: 426–8.
  • Bailar JC 3rd, Cicolella A, Harrison RJ, et al. IBM, Elsevier Sci-ence, and academic freedom. Arn J Ind Med. 2007; in press.
  • Melnick R.L. Suppression of crucial information in the IARC evaluation of DEHP. Rig Occup Environ Health, 2003; 9: 84–5; discussion 89.
  • Infante PF, Schuman LD, Dement J, Huff J. Fibrous glass and cancer, Arn J Ind Med, 1994: 26:559–84.
  • Infante PF, Schuman LD, Huff J. Fibrous glass insulation andcancer: response and rebuttal. Am J Ind Med. 1996; 30: 113–20.
  • Axelson O, Balbus JM, Cohen G, et al, Re: Regulatory toxicol-ogy and pharmacology. Int J Occup Environ Health, 2003; 9: 386-9; author reply 389-90.
  • Jacobson MF, Sharpe VA, Angell M, et al. Editorial policies on financial disclosure. Nat Neurosci. 2003; 6: 1001.
  • Ashford NA, Castleman B, Frank AL., et al The International Commission on Occupational Health (ICOH) and its influence on international organizations. Int J Occup Environ Health. 2002; 8: 156–62.
  • Richter ED, Berman T. Seattle and the ICOH: the view from the other side of the globe reditoriall. Int J Occup Environ Health. 2000; 6: 161–3
  • Wattersort A. ICOH and the pesticide industry [editorial]. Int J Occup Environ Health. 2000; 6: 73–6.
  • LaDou J. The asbestos cancer epidemic. Environ Health Per-spect. 2004: 112:285–90
  • Castleman B, Lernen R. The manipulation of international sci-entific organizations. Int J Occup Environ Health. 1998; 4: 53–5.
  • Castleman B. Global corporate policies arid international “double standards” in occupational and environmental health. Int J Occup Environ Health. 1999; 6: 61–4.
  • Watterson A. Pesticide health and safety and the work and impact of international agencies: partial successes and major failures. Int J Occup Environ Health. 2001; 7: 339–47 [the case study is largely drawn from this reference].
  • Sass JB, Colangelo A. European Union bans atrazine, while the United States negotiates continued use. Int J Occup Environ Health. 2006; 12: 260–7.
  • NIEHS and ACC establish grant program. Environ Health Per-spect. 2001; 109: 12.
  • GAO.NIH and EPA need to improve conflict of interest reviews for research arrangements with private sector entities. U.S. Gov-ernmental Accountability Office. GA0-05-191, February 2005.
  • 'roma& L. The IARC monographs program: changing attitudes towards public health, Int J Occup Environ Health, 2002;8:144 52.
  • Huff J. IARC monographs, industry influence, and upgrading, downgrading, and under-grading chemicals: a personal point of view. International Agency for Research on Cancer. Int J Occup Environ Health. 2002; 8: 249–70.
  • Melnick RL, Brody C, DiGiangi J, Huff J. The IARC evaluation of DEHP excludes key papers demonstrating carcinogenic effects. Int J Occup Environ Health. 2003; 9: 400–2.
  • Klaunig JE, Babich MA, Baetcke KP., et al PPARalpha agonist-induced rodent tumors: modes of action and human relevance, Crit Rev Toxica 2003; 33: 655–780.
  • Melnick EL, Karnel F, Huff J. Declaring chemicals “not carcino-genic to humans” requires validation, not speculation. Environ Health Perspect. 2003; 111: A203–4.
  • Mirer FE. Comment from the union participant in the IARC Working Group that downgraded DEHP. Int J Occup Environ Health. 2003; 9: 85–7.
  • Needleman H, Huffj. The International Agency for Research ort Cancer and obligate transparency. Lancet Oncol. 2005; 6: 920–1.
  • Abrams H, Anderson H, Anderson J., et al Business interests influence IPCS/WHO. Arch Environ Health, 1996; 51: 338–40.
  • Soffritti M, Belpoggi F, Degli Esposti D, Lambertini L, Mal& E, Rigano A. First experimental demonstration of the rnultipoten-tial carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environ Health Perspect. 2006; 114: 379–85.
  • NTP. Toxicology Studies of Aspartame (CAS No. 22839-47-0) in Genetically Modified (FVB Tg.AC Hemizygous) and B6.129-Cdkn2atmlRulp (N2) Deficient Mice and Carcinogenicity Studies of Aspartame in Genetically Modified [B6.129-Trp53tmlBrd (N5) Haplo-insufficient] Mice (Feed Studies). GMM-1. National Toxicology Program, Research Triangle Park, NC, October 2005; 1-222.
  • Gordon G. FDA resisted proposals to test aspartame for years. Star Tribune, November 22, 1996. http://www.rnindfully.org/food/aspartanie-fda-resisted22nov96.1nrn.
  • UCS. Restoring Scientific Integrity in Policymaking. An Investi-gation into the Bush Administration's Misuse of Science. Union of Concerned Scientists. 46 pages, 18 Feb 2004. http://www.ucsutsa.org/.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.